Zoetis Inc. with ticker code (ZTS) have now 15 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $248.00 and $172.12 with the average share target price sitting at $214.78. (at the time of writing). Given that the stocks previous close was at $177.04 this is indicating there is a potential upside of 21.3%. The day 50 moving average is $187.36 and the 200 moving average now moves to $178.73. The market capitalization for the company is 78.79B. The price for the stock stands currently at: $174.63 USD
The potential market cap would be $95,583,908,721 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 32.76, revenue per share of $20.06 and a 14.66% return on assets.
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. It commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company’s products are sold in more than 100 countries.
